PMID: 22568151May 10, 2012Paper

New antivirals against hepatitis C virus

Nihon rinsho. Japanese journal of clinical medicine
Naoya KatoKaku Goto

Abstract

Recently, first direct acting antiviral (DAA) against hepatitis C virus (HCV) has just approved in Japan. It is a first generation protease inhibitor, telaprevir. Telaprevir inhibits HCV NS3 & 4A serine protease, and combination with pegylated-interferon and ribavirin has now become a standard of care (SOC) for patients with genotype 1 high viral load hepatitis C. Fortunately, more than 50 new antivirals against HCV are under development including antivirals in preclinical trials. New antivirals are classified into several categories; (1) NS3 & 4A protease inhibitor, (2) NS5B polymerase inhibitor, (3) NS5A inhibitor, (4) host factor targeting antivirals, (5) interferon-related antivirals, and others. Combination of different classes of antivirals without interferon is expected to become a future SOC for hepatitis C.

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
Jia LiuGuangxiang Luo
Deutsche medizinische Wochenschrift
C Neumann-HaefelinR Thimme
Clinics in Liver Disease
Tania M Welzel, Stefan Zeuzem
© 2021 Meta ULC. All rights reserved